Ryogen and OriGene Technologies have announced today that they have entered into a nonexclusive license agreement whereby OriGene has licensed from R
Morphotek has announced that the European Patent Office has given a "Decision of Grant" regarding the Company's US Patent 6,921,666 entitled "Methods for Generating Hypermutable Yeast" and US Patent 6,737,268 entitled "A Method for Generating Genetical
Ranbaxy Laboratories Limited has announced that a Norwegian court handed down a favorable decision for Ranbaxy in its case against Pfizer, involving two patents on atorvastatin in Norway. Ator
Purdue Pharma L.P. of Stamford, Connecticut and Teva Pharmaceuticals USA, Inc. of North Wales, Pennsylvania have agreed to end their lawsuit concerning certain Purdue Pharma patents on OxyContin
Pfizer has said that a federal court in the Middle District of North Carolina has upheld the company's U.S. patent covering amlodipine besylate, the active ingredient in Norvasc, the world's most-presc
Mylan Laboratories Inc. has announced that the U.S. Court of Appeals for the Federal Circuit upheld a district court decision that Mylan's Oxybutynin products do not infringe a patent for DITROPAN XL an
SemBioSys Genetics has announced it has been granted U.S. patent 7,098,383 entitled "Methods for the production of multimeric immunoglobulins, and related compositions". The claims of the pat
ExonHit Therapeutics S.A., a drug and diagnostic discovery company, has announced that Merck & Co., Inc. has been granted a non-exclusive license to rights for research only under Patent US 6,881,
The Administrative Law Judge at the U.S. International Trade Commission (ITC) issued his Initial Determination concluding that Acambis plc's smallpox vaccine product (MVA3000) infringes two of Bava
Pfizer said today that the District Court of The Hague in the Netherlands has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor p
This invention is based on research conducted by Dr. Shinichi Kanno and Dr. Yasufumi Sato which is described in an article published in the journal Circulation in 1999 (Circulation. 1999;99:2682-2687).
The article describes that when the patented electrical stimulation sequence is applied to ischemic muscle that it significantly increases capillary density, thus increasing blood flow in the tissue.
Bioheart is focused on repairing damaged heart muscle with its MyoCell product, a myogenic cell composition made up of adult muscle stem cells called myoblasts. The company believes the issued claims will allow it to combine its MyoCell product with the said electrical stimulation sequence which could increase the blood supply to the transplanted cells and increase their survival. MyoCell is delivered to a patient's heart through the company's percutaneous needle injection catheter called the MyoCath.
Bioheart has two additional patents pending for utilizing electrical stimulation to enhance the repair of damaged heart muscle. The company envisions that these new electrical stimulation programs may be applied by bi-ventricular pacemakers to cell-transplanted regions of the heart in order to further improve patient outcomes.
http://www.bioheartinc.com/